Several new guidance documents issued by the FDA are poised to significantly impact the rare disease development landscape.

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos for FOP.

Boehringer in terms of licensing deals, with a majority of these agreements being oncology or immunology-focused.

Asahi Kasei has signed a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures for approximately ...

Novo Nordisk and Vivtex are to co-develop next-generation oral biologic therapies to treat obesity, diabetes and related ...

The organised crime group were selling unlicensed weight loss-substances online, using social media to market products.

IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.

Children are protected against fewer diseases as per the new schedule, which the states say will damage public health.

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

Our viewpoint is that in cases of ultra rare diseases where there is no commercial model or opportunity for traditional forms of investment, access to gene therapies could be provided via a clinical ...

This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...